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Abstract
Background: Previously, we reported that adoptively transferred perforin k/o (PKO), and IFN-γ k/o (GKO), or
perforin/IFN-γ double k/o (PKO/GKO) effector T cells mediated regression of B16BL6-D5 (D5) pulmonary
metastases and showed that TNF receptor signaling played a critical role in mediating tumor regression. In this
report we investigated the role of lymphotoxin-α (LT-α) as a potential effector molecules of tumor-specific
effector T cells.
Methods: Effector T cells were generated from tumor vaccine-draining lymph node (TVDLN) of wt, GKO, LT-
α deficient (LKO), or PKO/GKO mice and tested for their ability to mediate regression of D5 pulmonary
metastases in the presence or absence of LT-βR-Fc fusion protein or anti-IFN-γ antibody. Chemokine production
by D5 tumor cells was determined by ELISA, RT-PCR and Chemotaxis assays.
Results: Stimulated effector T cells from wt, GKO, or PKO/GKO mice expressed ligands for LT-β receptor (LT-
βR). D5 tumor cells were found to constitutively express the LT-βR. Administration of LT-βR-Fc fusion protein
completely abrogated the therapeutic efficacy of GKO or PKO/GKO but not wt effector T cells (p < 0.05).
Consistent with this observation, therapeutic efficacy of effector T cells deficient in LT-α, was greatly reduced
when IFN-γ production was neutralized. While recombinant LT-α1β2 did not induce apoptosis of D5 tumor cells
in vitro, it induced secretion of chemokines by D5 that promoted migration of macrophages.
Conclusion: The contribution of LT-α expression by effector T cells to anti-tumor activity in vivo was not
discernable when wt effector T cells were studied. However, the contribution of LT-β R signaling was identified
for GKO or PKO/GKO effector T cells. Since LT-α does not directly induce killing of D5 tumor cells in vitro, but
does stimulate D5 tumor cells to secrete chemokines, these data suggest a model where LT-α expression by
tumor-specific effector T cells interacts via cross-linking of the LT-βR on tumor cells to induce secretion of
chemokines that are chemotactic for macrophages. While the contribution of macrophages to tumor elimination
in our system requires additional study, this model provides a possible explanation for the infiltration of inate
effector cells that is seen coincident with tumor regression.
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Background
Adoptive transfer of tumor-specific T cells can induce
tumor regression in animal models and occasionally in
patients with cancer [1,2]. However, the mechanisms for
T cell mediated tumor regression are still under intensive
investigation. Tumor-specific T cells process multiple
effector molecules that can potentially participate in vari-
ous pathways leading to tumor destruction in vivo. Previ-
ously, we have documented that tumor regression
mediated by adoptive transfer of tumor-specific effector T
cells could be independent of either perforin or IFN-γ
pathways [3,4]. Recently, we also demonstrated that effec-
tor T cells lacking both perforin and IFN-γ could mediate
regression of pulmonary metastases of melanoma and fib-
rosarcoma, albeit the efficacy was greatly reduced [5],
demonstrating that perforin/granzyme and IFN-γ-depend-
ent mechanisms may have a compensatory role. However,
the fact that tumor regression did occur in a system lack-
ing both perforin and IFN-γ indicates that other mecha-
nisms, such as TNF-mediated pathways, can orchestrate
tumor regression [5].
IFN-γ is known to play a central role in the immune sur-
veillance against tumors [6-8]. In several murine tumor
models the therapeutic efficacy of adoptively transferred
effector T cells strongly correlates with their tumor-specific
IFN-γ release. Barth et al., and others observed a direct cor-
relation between the therapeutic efficacy of tumor infil-
trating lymphocytes (TIL) and their tumor-specific IFN-γ
production in a murine sarcoma model [9]. Similar corre-
lations between therapeutic efficacy and the tumor spe-
cific IFN-γ production were found for effector T cells
derived from lymph nodes (LN) draining the vaccine sites
of MCA-205 sarcoma or B16BL6 melanoma tumor cell
lines [10-13]. We also recently showed that a T1 pheno-
type is crucial for their therapeutic efficacy [14]. When
therapeutic effector T cells from wt TVDLN are cultured in
a T2 promoting cytokine milieu with IL-4 and anti-IL-12
antibody, they lost their therapeutic efficacy. So far, two
major classes of effector molecules that have been identi-
fied. First, effector molecules are able to mediate the direct
killing of tumor targets – perforin and granzymes in the
granules of CTL and ligands for death receptors on the cell
surface of T cells. Second, IFN-γ produced by tumor-spe-
cific T cells mediates tumor regression probably via the
activation of host macrophages [9,15].
While these studies indicate that IFN-γ plays a critical role
in the development of tumor immunity, we and others
have recently shown, that IFN-γ is not essential for the
priming of tumor specific effector cells in TVDLN or as an
effector molecule of adoptively transferred T-cells
[4,15,16]. This observation led to the hypothesis that
other T1 cytokines might play an essential role for the
therapeutic efficacy of tumor-specific effector T cells and
might compensate for the loss of IFN-γ in GKO mice.
Because no evidence for the generation of type 2 cytokine
T cell immune responses was observed in GKO mice, we
hypothesized that other type 1 cytokines produced by
adoptively transferred T cells were critical for the thera-
peutic efficacy. LT-βR ligand, a membrane bound heterot-
rimer known as LT-α1β2, was found to be expressed
abundantly on recently activated Th1 T cells [17-19]. In
addition, a recently described ligand for LT-βR (LIGHT)
was found to be expressed on activated lymphocytes and
shown to be able to induce secretion of chemokines and
apoptosis of some tumor cell lines [20-24]. Meanwhile,
LT-βR was found to be expressed on non-lymphoid cells
and the majority of tumor cell lines [18,25-27]. To inves-
tigate whether ligands for LT-βR, LT-α1β2 (and/or
LIGHT), could be the effector molecules of effector T cells
adoptive transfer experiments were designed. These stud-
ies examined how the presence or absence of IFN-γ or IFN-
γ and perforin affected the contribution of LTα to T cell
mediated-tumor regression. Effector T cells were gener-
ated from TVDLN of wt, GKO and adoptively transferred
into wt or GKO mice with established 3 day pulmonary
metastases of D5 tumor cells [5]. Signaling through LT-βR
was blocked by administration of LT-βR Fc after adoptive
transfer of T cells. Effector T cells deficient of membrane
bound lymphotoxin LT-α1β2 were also generated from
TVDLN by vaccinating RAG1 mice reconstituted with
naïve spleen cells from LKO mice. The therapeutic efficacy
of LKO effector T cells in an adoptive immunotherapy
model was compared in the presence or absence of IFN-γ
neutralizing antibody. To delineate a potential role of LT-
βR signaling in T cell mediated tumor regression, recom-
binant LT-α1β2 was used for the further investigation of
the effect of LT-βR signaling on D5 tumor cells in vitro.
Materials and methods
Mice
Female C57BL/6J (wt), GKO (C57BL/6-IFN-γ tm1Ts), and
LKO (C57BL/6 -LTtm1Sdz) mice were purchased from the
Jackson Laboratory (Bar Harbor, ME) and maintained in
a specific pathogen-free environment. Perforin and IFN-γ
double deficient (PKO/GKO) mice were generated as
described previously (5). Mice were generally 8 to 12
weeks old at the time of experimentation. Recognized
principles of laboratory animal care were followed (Guide
for the Care and Use of Laboratory Animals, National
Research Council, 1996), and all animal protocols were
approved by the Earle A. Chiles Research Institute Animal
Care and Use Committee.
Tumor cell lines
D5 is a poorly immunogenic subclone of the spontane-
ously arising B16BL6 melanoma [10] (provided by Dr. S.Journal of Translational Medicine 2007, 5:14 http://www.translational-medicine.com/content/5/1/14
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Shu, Cleveland Clinic Foundation, Cleveland, OH). An
early passage of the original BL6 tumor was provided by
Dr. E. Gorelick and was subcloned by limiting dilution
culture in Dr. S. Shu's laboratory. D5 exhibits low to unde-
tectable class I (H-2 Db and Kb) expression and no class II
expression. D5-G6 is a stable clone of D5 that was origi-
nally transduced with a murine GM-CSF retroviral MFG
vector (provided by Dr. M. Arca, University of Michigan,
Ann Arbor, MI) [44]. D5-G6 cells secrete approximately
200 ng/ml/106 cells/24 h GM-CSF.
Culture conditions
Lymphocytes and tumor cells were cultured in complete
medium (CM), which consisted of RPMI 1640 containing
0.1 mM nonessential amino acids, 1 mM sodium pyru-
vate, 2 mM L-glutamine, and 50 μg/ml of gentamicin sul-
fate (Bio Whittaker, Walkersville, MD.). This was further
supplemented with 50 mM 2-mercaptoethanol (Aldrich,
Milwaukee, WI, USA.), and 10% fetal bovine serum
(GIBCO BRL, Grand Island, NY). Tumor cells were har-
vested 2-to 3 times per week by brief trypsinization and
maintained in T-75 or T-150 culture flasks.
Generation of effector T cells from TVDLN
D5-G6 tumor cells were harvested by trypsinization,
washed twice with HBSS and resuspended at 2 × 107 cells
per ml. One million D5-G6 tumor cells were injected s.c.
into both hind and fore flanks of wt, or GKO mice. Eight
days following vaccination, the draining superficial
inguinal and auxiliary lymph nodes were harvested.
TVDLN were resuspended at 2 × 106 cells per ml in CM
and cultured in 24 well plates with 50 μl of a 1:40 dilution
of 2c11 ascites (anti-CD3) as described previously [3].
After two days of activation the T cells were harvested and
expanded in CM containing 60 IU rhIL-2/ml for three
additional days. T cells were then harvested, washed twice
in HBSS, counted and used in adoptive transfer and
cytokine release assays.
Adoptive immunotherapy
Experimental pulmonary metastases were established by
i.v. inoculation of 2 × 105 D5 tumor cells. Three days later
effector T cells were adoptively transferred i.v. via tail vein.
Starting on the day of T-cell infusion, mice received
90,000 IU recombinant human IL-2 (provided by Chiron,
Emeryville, CA) i.p. once per day for four days. Animals
were sacrificed 11 to 13 days following tumor inoculation
by CO2 narcosis and their lungs were harvested and fixed
in Fekete's solution. Where indicated, neutralizing LT-βR
Fc or control human IgG were administered i.v. before the
adoptive transfer of T cells and for the following three
days. The number of pulmonary metastases was counted
in a blinded fashion. Metastases that were too numerous
to count accurately were known to be greater than 250
metastases and were assigned a value of 250.
Statistical analysis
The statistical significance of differences in the number of
metastases between experimental groups was determined
by the Wilcoxon rank sum test. Two-sided p values of <
0.05 were considered significant. Each treatment group
consisted of at least 5 mice, and no animal was excluded
from the statistical evaluations.
Apoptosis induction
D5 tumor cells were incubated with different concentra-
tion of recombinant mouse LT-α1β2 (Sigma, MO) with or
without cycloheximide (CHX) (10 μg/ml) in 500 μl CM in
24 well plates. 24 hours later the cells were harvested,
washed twice with ice cold HBSS and resuspended in 100
μl Annexin binding buffer. Apoptosis was determined by
staining with Annexin-V-FITC (Pharmingen) and counter-
staining with 10 μl propidium (50 g/ml in PBS). 15 min-
utes later, the cells were analyzed by FACS and the
amount of apoptotic cells determined by calculating the
percentage of cells staining positive with Annexin-V.
RT-PCR
D5 cells were cultured in CM alone, with an indicated
number of effector T cells generated as above, or with an
indicated concentration of LT-α1β2. After 4–24 hours
incubation, the total RNA was extracted from D5 cells, or
after removal of T cells by washing three time with PBS,
using the Qiagen Rneasy mini kit (Qiagen, CA). 2 μg of
RNA was denatured and reversely transcribed to cDNA
using the oligo dT (15) primer (Roche) and MMLV reverse
transciptase (Invitrogen, CA). Thermocycling conditions
were: denaturing at 94°C for 30', annealing at 55°C for
30', and extending at 72°C for 30'. A total of 25 cycles
were performed. The DNA sequences of primers used are
shown in Table 1.
Measurement of cytokines
After activation and expansion TVDLN were washed,
resuspended in CM, supplemented with IL-2 (60 IU/ml)
and seeded at 4 × 106/2 ml/well in a 24 well plate. The
cells were either cultured without further stimulation or
stimulated with 2 × 105 D5, MCA-310 tumor cells, or
immobilized anti-CD3 (positive control). Supernatants
were harvested after 24 hours and assayed for the release
of KC and RANTES by ELISA using commercially available
reagents (Pharmingen). The concentration of cytokines in
the supernatant was determined by regression analysis.
Chemotactic assay
D5 tumors cells (105 well) were plated in the bottom
chamber of a 24 well transwell plate (Corning Costar,
Cambridge, MA) in CM. Two hours later they were stimu-
lated with or without LT-α1β2 (100 ng/ml). After 12
hours 3.5 × 105 DJ2PM macrophage cells were resus-
pended in 250 μl CM and plated into the upper chamberJournal of Translational Medicine 2007, 5:14 http://www.translational-medicine.com/content/5/1/14
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of a transwell plate (5 μm pore size). After 4 h the cells in
the bottom chamber were trypsinized, harvested, and
washed 2 × in PBS and stained with anti-CD11b antibody
(Pharmingen). The number of macrophages that migrated
into the lower well was determined by FACS analysis as
the percentage of CD11b positively stained cells.
Results
D5 tumor cells express LT-βR while effector T cells express 
the ligands
LT-βR expression was mainly found on non-lymphoid tis-
sues and tumor cell lines [18]. In contrast, the expression
of the ligands for LT-βR (LT-α1β2 or LIGHT) is highly
restricted to activated lymphocytes [18,21]. First, the D5
melanoma cell line used for the majority of our studies
was found to express a high level of LT-βR (Figure 1A).
Next, the expression of its cognate ligand on either wt or
GKO effector T cells generated from TVDLN was examined
by staining with LT-βR-Fc-fusion protein and PE-conju-
gated anti-human Fc antibody. Both wt and GKO TE
expressed a low but detectable level of binding to LT-βR-
Fc compared to control Fc fusion protein (509-Fc) (Figure
1B). After stimulation with anti-CD3 and CD28 antibod-
ies for 6 hours, a marked increase in binding of LT-βR-Fc
on both GKO and wt effector cells was observed. No dif-
ference of binding was found between wt and GKO effec-
tor T cells before or after in vitro activation with anti-CD3
and CD28 antibodies.
Blocking the therapeutic efficacy of GKO, but not wt 
effector T cells, by LT-βR-Fc
Because D5 tumor cells expressed the LT-βR, while wt and
GKO effector T cells expressed the cognate ligands for LT-
βR, a possible role of LT-βR signaling in tumor regression
after adoptive transfer was investigated in an experimental
pulmonary metastasis model. The LT-βR-Fc fusion protein
was administered i.v. before and after the adoptive trans-
fer of wt and GKO effector T cells into wt or GKO mice
bearing 3day established D5 pulmonary metastases. As
shown in table 2, blocking the LT-βR signaling did not
affect the therapeutic efficacy of wt effector T cells in 2 of
2 experiments performed, while the antitumor activity of
GKO effector T cells was abrogated in 3 of 4 consecutive
experiments. These experiments suggested a significant
role of LT-βR signaling for the tumor regression in certain
circumstances of tumor rejection if effector T cells failed to
produce IFN-γ.
IFN-γ neutralization blocked the therapeutic efficacy of 
LKO effector T cells
To further support the compensatory role of LT-βR and
IFN-γ, LKO effector T cells were generated from RAG1
mice reconstituted with naïve spleen cells from LT-α k/o
mice. Because LT-α k/o mice lack LN, it necessitates the
reconstitution of RAG1 mice for the generation of TVDLN.
As a control wt effector T cells were also generated from
RAG1 mice reconstituted with naïve wt spleen cells. In the
first experiment, both wt and LKO effector T cells were
able to mediate a complete tumor regression; the admin-
istration of anti-IFN-γ antibody significantly reduced the
efficacy of LKO effector T cells. In the second experiment
LKO effector T cells were less effective compared to wt T
cells. The administration of anti-IFN-γ antibody totally
abrogated the anti-tumor activity of LKO effector T cells
(Table 3). Blocking experiments with anti-IFN-γ antibody
were not done for wt effector T cells in this report, since we
have previously documented that the administration of
anti-IFN-γ antibody did not affect therapeutic efficacy of
wt effector T cells [4].
Blocking the therapeutic efficacy of PKO/GKO effector T 
cells by LT-βR-Fc
The above experiments suggested that LT-βR signaling
mediated by effector T cells contributed to tumor regres-
sion if IFN-γ was neutralized while the perforin-mediated
cytotoxicity was intact. Our previously published data
demonstrated that effector T cells from perforin and IFN-
γ double deficient (PKO/GKO) mice could still mediate
tumor regression in the adoptive immunotherapy model
(5). We investigated whether LT-βR signaling could con-
tribute to the tumor regression if PKO/GKO effector T
cells were used. As expected, data in Table 4 showed that
LT-βR-Fc could not block the function of wt effector T
cells, however, it significantly diminished the therapeutic
effacy of PKO/GKO effector T cells.
Table 1: Primer sequences used for RT-PCR
Gene Forward primer sequence  Reverse primer sequence
MIP-1α 5'-atg aag gtc tcc acc act gcc ctt g-3' 5'-ggc att cag ttc cag gtc agt gat-3'
MIP-1β 5'-gtt ctc agc acc aat ggg ctc tga-3' 5'-ctc tcc tga agt ggc tcc tcc tg-3'
IP-10 5'-cct atc ctg ccc acg tgt tg-3' 5'-cgc acc tcc aca tag ctt aca-3'
RANTES 5'-cat cct cac tgc agc cgc c-3' 5'-cca agc tgg cta gga cta gag-3'
MIG 5'-atg aag tcc gct gtt ctt ttc-3' 5'-tta tgt agt ctt cct tga acg ac-3'
HPRT 5'-gtt gga tac agg cca gac ttt gtt g-3' 5'-gag ggt agg atg gcc tat agg ct-3'Journal of Translational Medicine 2007, 5:14 http://www.translational-medicine.com/content/5/1/14
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LT-α1β2 failed to induce apoptosis of D5 tumor cells
LT-α1β2 can induce apoptosis directly in some adenocar-
cinoma cell lines and growth arrest in melanoma cells
[23,24]. One potential mechanism for LT-βR in T-cell
mediated tumor regression in our model is the direct
induction of apoptosis of D5 tumor cells. However, when
Table 2: The effect of LT-βR-Fc fusion protein administration on adoptive immunotherapy.
Adoptive immunotherapya Mean number of pulmonary metastasesb
Donor Hosts Number of T cells transferred Blocking proteinsb Exp.1 Exp.2 Exp.3 Exp.4
None wt 0 none 250 250
wt wt 35 hu IgG 21(5)d 52(13)d
wt wt 35 LTβR-Fc 33(6)d 78(11)d
wt GKO 0 None 243(60) 244(60) 250 250
GKO GKO 35 hu IgG 6(3)d 88(23)d 85(12)d 90(30)d
GKO GKO 35 LTβR-Fc 9(3)d 211(56)e 250e 250e
a) Mice were vaccinated s.c. with D5-G6 tumor cells and TVDLN were harvested 8 days later. Lymph node cells were stimulated in vitro with anti-
CD3 for two days and then expanded for three days in 60 IU/ml IL-2. Effector cells were harvested and 35 × 106 T cells were adoptively transferred 
into animals with established 3-day D5 pulmonary metastases. IL-2 (90,000 IU) was administered daily i.p. for four consecutive days following 
adoptive transfer.
b) Purified control human IgG or LT-βR-Fc (250 μg) was directly administered i.v. after adoptive transfer of the TE and for the following 3 days 
once per day.
c) Mice were sacrificed 13 days following i.v. inoculation of tumor and the number of pulmonary metastases enumerated in a blinded fashion. 
Results presented are the mean of 5 mice. Metastases that were too numerous to count accurately were known to be greater than 250 metastases 
and were assigned a value of 250.
d) p < 0.05 compared to IL-2 alone treated controls.
e) p > 0.05 compared to IL-2 alone treated controls.
Expression of LT-βR and its ligands Figure 1
Expression of LT-βR and its ligands. (A) D5 tumor cells were first stained with monoclonal rat anti-mouse LT-βR antibody 
(kind gift from Dr. M. Croft, La Jolla Institute for Allergy and Immunology) and isotype control antibody, and then with FITC-
labeled goat anti-rat IgG (Jackson immune research laboratory). After staining, cells were analyzed by flow cytometry. D5 
alone, filled histogram; isotype, dashed line; anti-mouse LT-βR, solid line. Effector T cells that were not stimulated (B) or stim-
ulated with anti-CD3 and CD28 antibodies for 6 hours (C) were incubated with mouse LT-βR-Fc fusion protein or control Fc 
fusion protein (509-Fc), and stained with PE-labeled goat anti-human Fc antibody. Stained cells were analyzed by flow cytome-
try. Solid line, control Fc fusion protein; dashed line, LT-βR Fc fusion protein.Journal of Translational Medicine 2007, 5:14 http://www.translational-medicine.com/content/5/1/14
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D5 tumor cells were incubated with different doses of LT-
α1β2 (1–100 ng/ml) with or without IFN-γ (200 U/ml)
for 24 hours, no direct cytotoxic effect was observed (Data
not shown). A low but detectable level of apoptosis (12%
at 100 ng/ml of LT-α1β2) was detected in tumor cells
incubated with LT-α1β2 in the presence of cycloheximide
after 24 hours of incubation (Figure 2). Since significant
difference in signaling and function was observed for TNF
family members, our data do not preclude the possibility
that membrane anchored LT-α1β2 on effector T cells
could still kill tumor cells directly. These data indicate that
a direct cytotoxicity of LT-βR signaling does not play a sig-
nificant role in our model. Therefore an indirect pathway
may provide a better explanation.
D5 tumor cells produce chemokines and induce 
chemotaxis of macrophages after incubation with effector 
T cells or treatment with LT-α1β2
Previously, we have shown that adoptive transfer of wt
and GKO TE induced an influx of macrophages and gran-
ulocytes into the lungs of mice with established pulmo-
nary metastases [4]. To examine whether the macrophage
chemotaxis is induced after coculture of effector T cells
and D5 tumor cells, an in vitro chemotaxis assay was used.
As shown in Figure 3a, supernatant from cultured D5
melanoma cells but not unstimulated effector T cells
exhibited macrophage chemotaxis activity. The number of
migrated macrophages was dramatically increased when
supernatant was collected from a co-culture of D5
melanoma and effector T cells. Next, we also examined
the expression of chemokines inducing macrophage
chemotaxis (KC, MCP-1, IP-10, and MIG) by either D5
melanoma cells or effector T cells after co-culturing. While
effector T cells did not express detectable KC, MCP-1, IP-
10 or MIG even after stimulation with anti-CD3 antibody,
surprisingly, they were expressed by D5 melanoma cells
after incubation with T cells (Figure 3b). D5 melanoma
cells cultured alone failed to express these ckemokines
(data not shown). This observation clearly supported our
earlier observation in vivo and potential contribution of
macrophages in tumor regression induced by adoptively
transferred T cells [4].
Degli-Esposti et al. have recently shown that activation of
the LT-βR induced the production of IL-8 and RANTES in
human A375 melanoma cells, indicating a possible regu-
latory role of LT-βR signaling in the recruitment of innate
anti tumor cells such as tumoricidal macrophages [28].
We hypothesized that one possible function of LT-βR sig-
naling in D5 tumor cells is to release chemokines that
induce chemotaxis of host macrophages. Therefore D5
cells were incubated with recombinant LT-α1β2 and
resultant condition media were collected. Using an in
vitro chemotactic assay, the condition media from D5
tumor cells after LT-α1β2 treatment, but not untreated
condition media were found to be able to attract the
migration of a macrophage cell line, DJ2P (Figure 4A).
Next, the expression of the chemokines, RANTES, KC,
MIP-1α, MIP-1β and MCP-1, by D5 tumor cells after LT-
α1β2 treatment was examined by RT-PCR. As shown in
Figure 3B, LT-α1β2 induced the expression of KC, IP-10,
RANTES, and MCP-1 in D5 tumor cells, but not the
expression of Mig, MIP-1α, and MIP1-β (data not shown).
The levels of KC and MCP-1 proteins in treated D5 super-
natant were also measured by ELISA (Figure 4C and 4D).
The highest level of mRNA and proteins were observed if
D5 cells were treated with the highest dose of LT-α1β2
used (100 ng/ml). Taken together, we envision that D5
tumor cells could induce the expression of membrane-
bound LT-α1β2 or LIHGT on adoptively transferred effec-
tor T cells, in turn, LT-α1β2 triggered the release of multi-
ple chemokines from D5 tumor cells and resulted in the
influx of macrophages into the tumor sites.
Discussion and conclusion
Previously, we have documented that granzyme, IFN-γ,
and TNF are three primary effector mechanisms by which
effector T cells could mediate tumor regression in adop-
tive transfer models [3-5]. The contribution by TNF family
members expressed by effector T cells is more difficult to
measure and less well appreciated. Our previous publica-
tion indicated that TNF could mediate tumor regression if
effector T cells were deficient of both perforin and IFN-γ
[15]. However, the blocking experiments with TNFR-Fc
fusion could not completely abrogate the tumor regres-
sion mediated by the adoptive transfer of perforin and
IFN-γ double deficient cells. Thus, other effector mole-
cules expressed by effector T cells could play a role even if
all three major effector molecules were absent or blocked.
In our present study we identified that LT-βR signaling
pathways also played a significant role if IFN-γ was absent
in the system. One possible mechanism for LT-βR signal-
ing is to stimulate chemokine secretion by D5 tumor cells
and induce macrophage recruitment.
Cross linking of LT-βR on tumor cells by membrane
bound ligands expressed on effector T cells after tumor
stimulation contributed to tumor regression. In vitro
experiments suggested a possible mechanism involving
the recruitment of macrophages rather than a direct kill-
ing mechanism by LT-α1β2. According to this notion,
Plautz et al. demonstrated that host macrophages are
important for the cross-presentation of tumor antigens to
adoptively transferred effector T cells during the phase of
tumor eradication [16]. A critical role of LT-βR has also
been demonstrated in the infectious, autoimmune dis-
eases and transplantation rejection models [29-32]. Lucas
et al. demonstrated that both TNFR and LT-βR pathways
played important roles in protective immunity againstJournal of Translational Medicine 2007, 5:14 http://www.translational-medicine.com/content/5/1/14
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Mycobacterium bovis BCG infection and LT-βR signaling is
critical for the development of Th1 immune response,
iNOS activation of macrophage, and granuloma forma-
tion [33]. LT-βR was used to reverse autoimmune diseases
in various models [29,32] and to prevent transplant rejec-
tion [31]. Our results added another important function
of LT-βR as an important tumor regression mechanism
independent of IFN-γ.
Because LT-βR-Fc can block LT-α1β2 and LIGHT, another
ligand of the TNF superfamily expressed on activated T-
cells and immature DC [21,34], both LT-α1β2 and LIGHT
on effector T cells could contribute to the tumor regres-
sion observed in our experiments. In addition to LT-βR,
LIGHT can bind to other two receptors, herpes virus entry
mediator (HVEM) and decoy receptor 3/TR6 [21,35]. Sev-
eral studies indicate that LIGHT can trigger apoptosis as
well as cell activation depending on the expression of dif-
ferent receptors on the targeted cells [20,22]. Shaikh et al.
showed that the constitutive expression of LIGHT on T
cells led to inflammation and tissue destruction [36].
Tamada et al. showed that expression of LIGHT by trans-
planted tumors led to increased lymphocytic infiltrates,
tumor necrosis and enhanced T cell cyotoxicity [37]. Sim-
ilarly, Schrama et al. demonstrated that targeting LT-α3 to
tumor resulted in tumor destruction via the formation of
lymphoid-like structure in tumor sites [38]. It has been
well documented that LT-βR signaling, and to a lessor
Table 4: The effect of LT-βR-Fc fusion protein administration on adoptive immunotherapy.
Adoptive immunotherapya Mean number of pulmo-
nary metastasesb
Donor T cells Hosts Number of T cells 
transferred
Blocking proteinsb
wt wt 0 none 192(28)
wt wt 35 none 0(0)
wt wt 35 hu IgG 0(0)
wt wt 35 LTβR-Fc 0(0)
PKO/GKO wt 70 None 0(0)
PKO/GKO wt 70 hu IgG 0(0)
PKO/GKO wt 70 LTβR-Fc 78(50) d
a) Wild type (wt) or perforin and IFN-γ double deficient (PKO/GKO) mice were vaccinated s.c. with D5-G6 tumor cells and TVDLN were 
harvested 8 days later. Lymph node cells were stimulated in vitro with anti-CD3 for two days and then expanded for three days in 60 IU/ml IL-2. 
Effector cells were harvested and 35 × 106 T cells were adoptively transferred into animals with established 3-day D5 pulmonary metastases. IL-2 
(90,000 IU) was administered daily i.p. for four consecutive days following adoptive transfer.
b) Purified control human IgG or LT-βR-Fc (250 μg) was directly administered i.v. after adoptive transfer of the TE and for the following 3 days 
once per day.
c) Mice were sacrificed 13 days following i.v. inoculation of tumor and the number of pulmonary metastases enumerated in a blinded fashion. 
Results presented are the mean of 5 mice.
d) p < 0.05 compared to IL-2 alone treated controls.
Table 3: The effect of IFN-γ neutralization on adoptive immunotherapy.
Adoptive immunotherapya Mean number of pulmonary metastasesb
Donor Hosts Number of T cells 
transferred
Blocking proteinsb Exp.1 Exp.2
None wt 0 none 250 250
LKO wt 15 rat IgG 0 d 81(35)d
LKO wt 15 Anti-IFN-γ 39(29)d 242(8)e
a)Rag1k/o mice were reconstituted with naïve 20 × 106 naïve spleen cells from naïve wt or LT-α k/o mice. They were then vaccinated s.c. with D5-
G6 tumor cells, and TVDLN were harvested 8 days later. Lymph node cells were stimulated in vitro with anti-CD3 for two days and then expanded 
for three days in 60 IU/ml IL-2. Effector cells were harvested and 15 × 106 T cells were adoptively transferred into animals with established 3-day 
D5 pulmonary metastases. IL-2 (90,000 IU) was administered daily i.p. for four consecutive days following adoptive transfer.
b)Purified control rat IgG or rat anti-mouse IFN-γ antibody (250 μg) was directly administered i.v. after adoptive transfer of the T cells and for the 
following 3 days once per day.
c) Mice were sacrificed 13 days following i.v. inoculation of tumor and the number of pulmonary metastases enumerated in a blinded fashion. 
Results presented are the mean and SE of 5 mice. Metastases that were too numerous to count accurately were known to be greater than 250 
metastases and were assigned a value of 250.
d) p < 0.05 compared to IL-2 alone treated controls.
e) p > 0.05 compared to IL-2 alone treated controls.Journal of Translational Medicine 2007, 5:14 http://www.translational-medicine.com/content/5/1/14
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extent, TNFR signaling is critical for the development and
maturation of secondary lymphoid tissues [18,39]. One
critical function of LT-βR is the activation of a chemokine-
driven positive feedback loop required for the organiza-
tion of lymphoid follicles [40]. Interestingly, a recent
reported LT-βR signaling by LIGHT at tumor sites could
lead to eradiation of well-established tumors via the
recruitment of immune cells, including naïve T cells, and
the formation of lymphoid-like structure inside tumors
[41]. We hypothesized that one important function for
LT-βR in our model is the activation of a similar chemok-
ine-driven positive feedback loop by the adoptively trans-
ferred effector T cells that results in the recruitment of host
innate cells, such as macrophages and dendritic cells, indi-
rectly contributing to the tumor destruction process.
Although it is conceivable that blocking with LT-βR might
prevent the initial infiltration of adoptive effector T cells
into the lungs, we did not observe a difference in the traf-
ficking of CFSE-labeled effector T cells with or without LT-
βR Fc treatment (data not shown). Thus, at least for our
pulmonary metastases model, the effect of LT-βR blockage
was unlikely due to the prevention of T cell trafficking.
The fact that the therapeutic efficacy of wt effector T cells
was not affected by LT-βR blockage is an additional argu-
ment against this possibility. The chemokines RANTES,
MCP-1 and KC are induced in most inflammatory condi-
tions and their expression correlates with the influx of
macrophages into inflammatory sites [42-44]. In our in
vitro experiments we detected the expression of RANTES,
IP-10, KC and MCP-1 by D5 tumor cells after incubation
with recombinant LT-α1β2. While growing tumors can
likely counteract the immune system to insure their pro-
gression, it is of interest to note that the effector T cells
may co-opt tumor cells themselves to contribute to their
own demise. Further investigations into this paradox are
warranted.
Together with other published data, our current study sug-
gests that tumor-reactive T cells are capable of mediating
tumor regression via a number of compensatory effector
mechanisms. Recently, the clinical significance of tumor
infiltrating lymphocytes was highlighted in multiple stud-
ies of human tumors, including colon cancer, ovarian can-
cer, and lymphoma [46-48]. Because not all possible
effector molecules were examined, it will be of great inter-
est to examine which particular effector mechanisms can
LT-α1β2 failed to induce apoptosis of D5 tumor cells Figure 2
LT-α1β2 failed to induce apoptosis of D5 tumor cells. D5 tumor cells were incubated with indicated amount of murine 
recombinant LT-α1β2 with or without protein synthesis inhibitor cycloheximide (10 μg/ml) for 24 hours. Cells were then 
stained with Annexin-FITC. The percentage of cells that underwent apoptosis was determined by FACS analysis.Journal of Translational Medicine 2007, 5:14 http://www.translational-medicine.com/content/5/1/14
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be directly correlated to the patient's survival. Subse-
quently, strategies that induce these properties in T cells ex
vivo could be applied to the adoptive immunotherapy of
cancer, while alternatives that can induce these properties
in vivo may serve as a useful adjunct for cancer vaccine
strategies.
Abbreviations
PKO, perforin knock out
GKO, IFN-γ knock out
PKO/GKO, perforin and IFN-γ double knock out
LKO, lymphotoxin knock out
LT-βR, lymphotoxin beta receptor
LT-α1β2, lymphotoxin α1β2 heterotrimer
LIHGT, homologous to lymphotoxin, exhibits inducible
expression, and competes with HSV glycoprotein D for
herpes virus entry mediator
TVDLN, tumor vaccine draining lymph node
D5, a poorly immunogenic clone of B16F10 melanoma
D5-G6, a D5 clone that producing murine GM-CSF
KC, a mouse homolog of human chemokine gro-alpha
(CXCL1)
IP-10, γ-interferon-inducible protein
MCP-1, monocyte chemoattractant protein-1
Mig, monokine induced by γ-interferon
MIP-1, macrophage inflammatory protein
Expression of Chemokine by D5 melanoma cells and Chemotaxis of Macrophages In Vitro Figure 3
Expression of Chemokine by D5 melanoma cells and Chemotaxis of Macrophages In Vitro. (A) Macrophage 
chemotactic activity of D5 supernatant after incubation with effector T cells. Supernatant derived from cultured D5 tumor cells 
or D5 tumor cells that were cocultured with effector T cells for 24 hours were plated in the lower chamber of a transwell 
plate. The number of DJ2P macrophage cells placed on the upper chambers that trans-migrated into the lower chamber was 
determined by FACS analysis with FITC-labeled antiCD11b antibody. (B) Chemokine expression by D5 tumor cells or effector 
T cells with and without stimulation. Expression of chemokines by D5 tumor cells after cocluture with effector T cells and 
removal of T 24 hours late or effector T cells stimulated with anti-CD3 antibody for 24 hours were analyzed by RT-PCR. 
HPRT expression was used for the control of total mRNA.Journal of Translational Medicine 2007, 5:14 http://www.translational-medicine.com/content/5/1/14
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Effect of recombinant LT-α1β2 treatment on D5 tumor cells Figure 4
Effect of recombinant LT-α1β2 treatment on D5 tumor cells. (A) Macrophage chemotactic activity of D5 supernatant 
after treatment with LT-α1β2. Supernatant derived from cultured D5 tumor cells or D5 tumor cells that were treated with 
recombinant LT-α1β2 were plated in the lower chamber of a transwell plate. The number of DJ2P macrophage cells placed on 
the upper chambers that trans-migrated into the lower chamber was determined by FACS analysis with FITC-labeled 
antiCD11b antibody. (B) Chemokine expression by D5 tumor cells induced by LT-α1β2. Expression of chemokines by D5 
tumor cells before or after LT-α1β2 treatment were analyzed by RT-PCR. HPRT expression was used for the control of total 
mRNA. Production of MCP-1 (C) and KC (D) and by D5 tumor cells in the supernatant after LT-α1β2 treatment was meas-
ured by ELISA. The error bars represents standard error of 2–3 experiments.Journal of Translational Medicine 2007, 5:14 http://www.translational-medicine.com/content/5/1/14
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